cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Enochian Biosciences Inc
8 own
4 watching
Current Price
$0.79
$0
(0.41%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
44.09M
52-Week High
52-Week High
3.83
52-Week Low
52-Week Low
0.7238
Average Volume
Average Volume
0.08M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization44.09M
icon52-Week High3.83
icon52-Week Low0.7238
iconAverage Volume0.08M
iconDividend Yield--
iconP/E Ratio--
What does the Enochian Biosciences Inc do?
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Read More
How much money does Enochian Biosciences Inc make?
News & Events about Enochian Biosciences Inc.
Globe Newswire
2 months ago
Turning the Page; A Promising FutureLOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Accelerated Pre-Investigational New Drug (Pre-IND) submission to the US Food and Drug Administration (FDA) for potential cancer product due to additional promising results from studies in a commonly...
Globe Newswire
2 months ago
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted ...
Globe Newswire
2 months ago
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for ...
Globe Newswire
7 months ago
Initial, Pre-Clinical Animal Study Results Show Potential To Effectively Treat Pancreatic CancerLOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Today, Enochian BioSciences (the Company) announced that it was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be...
Globe Newswire
8 months ago
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Enochian Biosciences, Inc. (NASDAQ: ENOB), Weber, Inc. (NYSE: WEBR), Coinbase Global, ...
Frequently Asked Questions
Frequently Asked Questions
What is Enochian Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Enochian Biosciences Inc shares?
plus_minus_icon
How can I buy Enochian Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Enochian Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Enochian Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Enochian Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Enochian Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Enochian Biosciences Inc?
plus_minus_icon
What percentage is Enochian Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Enochian Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.79
$0
(0.41%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00